

# Enhanced Recovery after Cardiac Surgery

## The impact of complications in cardiac surgery

Complications after cardiac surgery may be widespread and are associated with increases in cost of care, length of stay, readmissions, and mortality.<sup>1,2,3,4</sup>



Up to  
**15%**  
of patients may have  
**1+ complications**<sup>1</sup>



Approximately  
**\$36k**  
increase in cost  
may be due to acute  
kidney injury (AKI)<sup>2</sup>



Up to  
**68%**  
of patients with multiple  
major morbidities may have  
**prolonged hospital LOS**<sup>1</sup>




Approximately  
**1 in 5**  
patients may require  
**readmission**<sup>3</sup>




Major infection or AKI  
may be associated with  
**10x**  
increase  
in mortality<sup>1,2,4</sup>

## The benefit of perioperative goal-directed therapy (PGDT) in cardiac surgery

Applying PGDT protocols to optimize flow and oxygen delivery improves outcomes in critically ill patients and patients undergoing major surgery<sup>6,8,9,10</sup>



Complications arise from excessive and insufficient volume administration<sup>5</sup>



PGDT using advanced hemodynamic parameters helps to maintain optimal volume administration<sup>7</sup>

May  
reduce  
morbidity  
**60%-70%**<sup>8,10</sup>

May  
reduce  
AKI  
**23%**<sup>11</sup>

May  
reduce  
hospital LOS  
**1-5 days**<sup>8,9,10</sup>



**Class I recommendation:**

***“Goal-directed fluid therapy is recommended to reduce postoperative complications.”***

---

References

1. Crawford, T., et al. Complications After Cardiac Operations: All Are Not Created Equal. *Ann Thorac Surg*, 2017.
2. Alshaikh, H., et al. Financial Impact of Acute Kidney Injury After Cardiac Operations in the United States. *Ann Thorac Surg*, 2018.
3. Iribarne A., Chang H, Alexander J, et al. Readmissions After Cardiac Surgery: Experience of the National Institutes of Health/Canadian Institutes of Health Research Cardiothoracic Surgical Trials Network. 2014;98:1274-80. (Study looked at all cause readmissions within 65 days after the operation.)
4. Gelijns, A., et al. Management Practices and Major Infections After Cardiac Surgery. *Journal of the American College of Cardiology*, 2014.
5. Ronco, C. Diagnosis and management of fluid overload in heart failure and cardio-renal syndrome: The “5B” approach. *Seminars in Nephrology* 2012;32:129-141.
6. Fergerson, B., et al. Goal-Directed Therapy in Cardiac Surgery: Are We There Yet? *Journal of Cardiothoracic and Vascular Anesthesia*, 2013.
7. Michard F, Changes in arterial pressure during mechanical ventilation. *Anesth*, 2005.
8. Aya HD., Cecconi, M., Rhodes, A., Goal-directed therapy in cardiac surgery: a systematic review and meta-analysis *BJA*, 2013.
9. Li, Peng, et al. Significance of perioperative goal-directed hemodynamic approach in preventing postoperative complications in patients after cardiac surgery: a meta-analysis and systematic review. *Annals of Medicine*, 2017.
10. Osawa, E., et al. Effect of Perioperative Goal-Directed Hemodynamic Resuscitation Therapy on Outcomes Following Cardiac Surgery: A Randomized Clinical Trial and Systematic Review. *Critical Care Medicine*, 2016.
11. Meersch, M., et al. Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial. *Intensive Care Med*, 2017.
12. Engelman, et al. Enhanced Recovery After Surgery (ERAS): An Expert Consensus Statement in Cardiac Surgery. *Enhanced Recovery After Surgery-Cardiac Surgery*, 2018.

All information provided by Edwards Lifesciences is gathered from third party sources and is presented for informational purposes only. This information is not intended to describe, recommend, or suggest any use, feature, or benefit of any Edwards product and does not constitute reimbursement, medical, or legal advice. Edwards makes no representation or warranty regarding the information or its completeness, accuracy, or timeliness. It is not intended to make a recommendation regarding clinical practice. Laws, regulations, and payer policies concerning reimbursement are complex and change frequently; service providers are responsible for all decisions relating to clinical services, coding, and reimbursement submissions. Accordingly, Edwards strongly recommends consultation with payers, reimbursement specialists, and/or legal counsel regarding coding, coverage, and reimbursement matters.

Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2019 Edwards Lifesciences Corporation. All rights reserved. PP--US-3604 v1.0

Edwards Lifesciences • One Edwards Way, Irvine CA 92614 USA • edwards.com

